Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Lilly has also said it has begun manufacturing the drug in order to stockpile supply ahead of a commercial launch, which should help avoid shortages experienced when early demand for the injectables ...

Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss ...

Wegovy, a brand name for semaglutide, is a GLP-1 inhibitor medication that targets the parts of the brain that regulate ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...